Peeling Back The Layers: Exploring Conmed Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Over the past three months, six analysts have shared their insights on Conmed (NYSE:CNMD), with opinions ranging from bullish to bearish. The average 12-month price target has decreased by 7.42% to $89.5. Analysts from firms like Piper Sandler, Stifel, Wells Fargo, and Needham have lowered their price targets, reflecting a cautious outlook on Conmed's future performance.
August 01, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Analysts have lowered their price targets for Conmed, with the average 12-month target now at $89.5, down 7.42% from the previous average. This reflects a cautious outlook on Conmed's future performance.
The reduction in price targets by multiple analysts indicates a cautious outlook on Conmed's future performance. This is likely to have a negative short-term impact on the stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100